INNOCARE(09969),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

09969 INNOCARE

Noon Closed 03-11 12:05:00

11.860

-0.320

-2.63%

High12.270	Low11.850	Vol1.67M
Open12.180	D1 Closing12.180	Amplitude3.45%
Mkt Cap20.90B	Tradable Cap17.72B	Total Shares1.76B
T/O19.95M	T/O Rate0.11%	Tradable Shares1.49B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"INNOCARE","latestPrice":11.86,"timestamp":1773201900007,"preClose":12.18,"halted":0,"volume":1669000,"delay":0,"changeRate":-0.02627257799671595,"floatShares":1494000000,"shares":1762000000,"eps":-0.27,"marketStatus":"Noon Closed","change":-0.32,"latestTime":"03-11 12:05:00","open":12.18,"high":12.27,"low":11.85,"amount":19949395,"amplitude":0.034483,"askPrice":11.9,"askSize":3000,"bidPrice":11.86,"bidSize":20000,"shortable":3,"etf":0,"ttmEps":-0.143,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1773205200000},"marketStatusCode":3,"adr":0,"listingDate":1584892800000,"exchange":"SEHK","adjPreClose":12.18,"openAndCloseTimeList":[[1773192600000,1773201600000],[1773205200000,1773216000000]],"volumeRatio":0.53989,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"Innocare Pharma Limited","latestPrice":23.44,"timestamp":1773199800000,"preClose":23.81,"halted":0,"volume":3790600,"delay":0,"premium":"-55.64"}},"requestUrl":"/m/hq/s/09969","defaultTab":"news","newsList":[{"id":"2618642250","title":"Assessing InnoCare Pharma (SEHK:9969) Valuation After Priority Review Milestone For Zurletrectinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2618642250","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618642250?lang=en_us&edition=fundamental","pubTime":"2026-03-08 17:18","pubTimestamp":1772961526,"startTime":"0","endTime":"0","summary":"InnoCare Pharma (SEHK:9969) has drawn fresh attention after China’s drug regulator granted priority review to its next generation TRK inhibitor zurletrectinib for pediatric NTRK fusion solid tumors, alongside inclusion in the CDE’s SPARK Program.\nSee our latest analysis for InnoCare Pharma.\nThe priority review news comes after a mixed stretch for the shares. A 1-day share price return of 5.44% lifted the stock to HK$11.83, while the 30-day and 90-day share price returns of 7.87% and 17.10%...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/assessing-innocare-pharma-sehk9969-valuation-after-priority","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/assessing-innocare-pharma-sehk9969-valuation-after-priority","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["09969","BK1574","BK1161"],"gpt_icon":0},{"id":"1184953941","title":"INNOCARE (09969) Monthly Securities Movements Show No Change in Issued Share Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=1184953941","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184953941?lang=en_us&edition=fundamental","pubTime":"2026-03-04 17:09","pubTimestamp":1772615363,"startTime":"0","endTime":"0","summary":"INNOCARE (09969) released its Monthly Return for the month ended 28 February 2026, reporting no adjustment to its authorised share capital of 25.00 billion shares at a par value of USD 0.000002,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"gpt_icon":0},{"id":"1119185631","title":"INNOCARE Shares Surge Over 4% in Late Trading as Phase 3 Trial for BCL2 Inhibitor Combo Completes Patient Enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=1119185631","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119185631?lang=en_us&edition=fundamental","pubTime":"2026-02-27 15:40","pubTimestamp":1772178020,"startTime":"0","endTime":"0","summary":"INNOCARE (09969) saw its shares rise more than 4% in late trading. At the time of writing, the stock was up 3.96%, trading at HK$12.08, with a turnover of HK$44.72 million. The movement follows the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","BK4588","688428","VT","09969","BK1161","BK1574","BK4585","BK0239"],"gpt_icon":0},{"id":"2613176599","title":"A Look At InnoCare Pharma (SEHK:9969) Valuation As Dermatology Trials For Soficitinib Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2613176599","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613176599?lang=en_us&edition=fundamental","pubTime":"2026-02-24 11:28","pubTimestamp":1771903681,"startTime":"0","endTime":"0","summary":"InnoCare Pharma (SEHK:9969) has drawn fresh investor attention after dosing the first patient in a Phase II/III trial of TYK2 inhibitor soficitinib for chronic spontaneous urticaria, alongside progress across multiple late stage dermatology programs.\nSee our latest analysis for InnoCare Pharma.\nThe new dermatology trial news comes after a mixed price patch, with a 7.71% 1 month share price return and a 1 year total shareholder return of 63.92%, even though the 90 day share price return shows...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/a-look-at-innocare-pharma-sehk9969-valuation-as-dermatology","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/a-look-at-innocare-pharma-sehk9969-valuation-as-dermatology","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","09969","PRGS","BK4097","LU2065732104.USD","BK1161"],"gpt_icon":0},{"id":"2611548367","title":"Assessing InnoCare Pharma (SEHK:9969) Valuation As Its Autoimmune Pipeline Advances Through Key Trial Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2611548367","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611548367?lang=en_us&edition=fundamental","pubTime":"2026-02-16 18:23","pubTimestamp":1771237397,"startTime":"0","endTime":"0","summary":"InnoCare Pharma (SEHK:9969) has drawn fresh attention after dosing the first patient in a Phase II/III trial of its TYK2 inhibitor soficitinib for chronic spontaneous urticaria, alongside progress across several other dermatology indications.\nSee our latest analysis for InnoCare Pharma.\nDespite the steady stream of trial updates and the recent IND approval for ICP-538, InnoCare Pharma’s 90 day share price return decline of 14.51% contrasts with a 1 year total shareholder return of 91.23%,...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/assessing-innocare-pharma-sehk9969-valuation-as-its-autoimmu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/assessing-innocare-pharma-sehk9969-valuation-as-its-autoimmu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["09969","BK1574","BK1161"],"gpt_icon":0},{"id":"1186945606","title":"Innocare's Cancer Drug New Indication Recommended for Priority Review","url":"https://stock-news.laohu8.com/highlight/detail?id=1186945606","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186945606?lang=en_us&edition=fundamental","pubTime":"2026-02-11 15:03","pubTimestamp":1770793415,"startTime":"0","endTime":"0","summary":"On February 10, the latest announcement from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration indicated that the orally disintegrating tablet formulation of...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","09969","BK1161","BK1574","688428"],"gpt_icon":0},{"id":"1194307897","title":"Innocare Shares Surge Over 11% on First-Ever Profitability Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=1194307897","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194307897?lang=en_us&edition=fundamental","pubTime":"2026-02-06 10:50","pubTimestamp":1770346230,"startTime":"0","endTime":"0","summary":"Innocare (09969) rose more than 11% again, with the stock up 11.08% to HK$13.15 at the time of writing, and a turnover of HK$155 million. The company issued a positive profit alert, forecasting...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688428","BK4588","VXUS","BK1161","09969","BK4585","BK1574","VT"],"gpt_icon":0},{"id":"1124150543","title":"INNOCARE Shares Surge Over 4% in Morning Session as Company Posts First-Ever Profit, Core Drug Orelabrutinib Drives Significant Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1124150543","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124150543?lang=en_us&edition=fundamental","pubTime":"2026-02-05 11:01","pubTimestamp":1770260466,"startTime":"0","endTime":"0","summary":"INNOCARE (09969) saw its shares rise more than 4% during the morning trading session. As of the time of writing, the stock was up 3.95%, trading at HK$11.83, with a turnover of HK$38.70 million. The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","688428","VT","BK4588","BK0239","BK1574","09969","VXUS","BK1161"],"gpt_icon":0},{"id":"1143348970","title":"InnoCare Pharma (09969) Announces Monthly Return for January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1143348970","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143348970?lang=en_us&edition=fundamental","pubTime":"2026-02-04 16:45","pubTimestamp":1770194734,"startTime":"0","endTime":"0","summary":"InnoCare Pharma Limited released its monthly return on movements in securities for the period ended January 31, 2026. The authorized share capital remained at 25,000,000,000 ordinary shares with a...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"gpt_icon":0},{"id":"2608378618","title":"A Look At InnoCare Pharma (SEHK:9969) Valuation As It Targets First Profit On 2025 Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2608378618","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608378618?lang=en_us&edition=fundamental","pubTime":"2026-02-02 11:17","pubTimestamp":1770002277,"startTime":"0","endTime":"0","summary":"InnoCare Pharma (SEHK:9969) is back in focus after the company projected an improvement in its 2025 financial performance, supported by stronger drug sales and an anticipated move into profitability for the first time.\nSee our latest analysis for InnoCare Pharma.\nThat profit outlook comes after a mixed share price run, with the latest close at HK$11.72. The 1 year total shareholder return of 111.93% contrasts with a 5 year total shareholder return decline of 44.06%. This suggests recent...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/a-look-at-innocare-pharma-sehk9969-valuation-as-it-targets-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/a-look-at-innocare-pharma-sehk9969-valuation-as-it-targets-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["09969","BK1574","BK1161"],"gpt_icon":0},{"id":"1193384375","title":"Zhitong Hong Kong Stock Morning Briefing | State Council Issues Plan to Accelerate New Growth Points in Service Consumption, Gold and Silver Plunge Overnight","url":"https://stock-news.laohu8.com/highlight/detail?id=1193384375","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193384375?lang=en_us&edition=fundamental","pubTime":"2026-01-30 07:09","pubTimestamp":1769728150,"startTime":"0","endTime":"0","summary":"The General Office of the State Council has issued the \"Work Plan for Accelerating the Cultivation of New Growth Points in Service Consumption.\" This plan aims to optimize and expand the supply of...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06979","BK4588","BK1192","VT","BK4585","09969","BK1574","AGQ"],"gpt_icon":1},{"id":"2607295702","title":"InnoCare Pharma Expects Turnaround to Profit in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2607295702","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607295702?lang=en_us&edition=fundamental","pubTime":"2026-01-29 17:18","pubTimestamp":1769678339,"startTime":"0","endTime":"0","summary":"InnoCare Pharma  said it expects a turnaround to profit in 2025, according to a Hong Kong bourse filing Thursday.The firm expects 633 million yuan in attributable profit for the year, compared with a loss of 441 million yuan in 2024.Operating revenue is expected to rise 134% year-on-year to 2.37 billion yuan, the firm said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["09969","BK1161","BK1574"],"gpt_icon":0},{"id":"2606937862","title":"Pinning Down InnoCare Pharma Limited's (HKG:9969) P/S Is Difficult Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2606937862","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606937862?lang=en_us&edition=fundamental","pubTime":"2026-01-26 08:37","pubTimestamp":1769387871,"startTime":"0","endTime":"0","summary":"There wouldn't be many who think InnoCare Pharma Limited's ( HKG:9969 ) price-to-sales (or \"P/S\") ratio of 12.5x is...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/pinning-down-innocare-pharma-limiteds-hkg9969-ps-is-difficul-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/pinning-down-innocare-pharma-limiteds-hkg9969-ps-is-difficul-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["09969","BK1574","BK1161"],"gpt_icon":0},{"id":"2601694118","title":"An Intrinsic Calculation For InnoCare Pharma Limited (HKG:9969) Suggests It's 45% Undervalued","url":"https://stock-news.laohu8.com/highlight/detail?id=2601694118","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601694118?lang=en_us&edition=fundamental","pubTime":"2026-01-06 08:54","pubTimestamp":1767660877,"startTime":"0","endTime":"0","summary":"Key Insights Using the 2 Stage Free Cash Flow to Equity, InnoCare Pharma fair value estimate is HK$23.47 Current share...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/an-intrinsic-calculation-for-innocare-pharma-limited-hkg9969","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/an-intrinsic-calculation-for-innocare-pharma-limited-hkg9969","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","DCF","BK1161","TV","BK1574","FCF","09969","BK4100"],"gpt_icon":0},{"id":"1195454661","title":"INNOCARE (09969) Grants 1.4 Million Restricted Share Units","url":"https://stock-news.laohu8.com/highlight/detail?id=1195454661","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195454661?lang=en_us&edition=fundamental","pubTime":"2025-12-31 17:20","pubTimestamp":1767172814,"startTime":"0","endTime":"0","summary":"INNOCARE (09969) announced that on December 31, 2025, the company granted 1.4 million restricted share units to two grantees under the 2023 Equity Incentive Plan. This represents approximately 0.08% of the company's total issued share capital as of the date of this announcement.","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","09969","BK1161","BK1574","BK0239"],"gpt_icon":0},{"id":"1101786163","title":"Guoyuan International Sets INNOCARE (09969) Target Price at HK$16.81 with \"Buy\" Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1101786163","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101786163?lang=en_us&edition=fundamental","pubTime":"2025-12-24 15:08","pubTimestamp":1766560115,"startTime":"0","endTime":"0","summary":"Guoyuan International released a research report projecting INNOCARE's (09969) revenue for 2025-27 at RMB2.01 billion, RMB2.06 billion, and RMB2.56 billion, respectively, with net profits of RMB117...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969","BK1161","BK0239","688428","BK1574"],"gpt_icon":0},{"id":"2593075124","title":"Is InnoCare Pharma (SEHK:9969) Quietly Recasting Its Future Around Autoimmune Dermatology?","url":"https://stock-news.laohu8.com/highlight/detail?id=2593075124","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593075124?lang=en_us&edition=fundamental","pubTime":"2025-12-21 18:12","pubTimestamp":1766311968,"startTime":"0","endTime":"0","summary":"Earlier this month, InnoCare Pharma received CDE approval in China to begin a Phase II/III trial of its novel TYK2 inhibitor soficitinib for chronic spontaneous urticaria, expanding its autoimmune and dermatology pipeline.\nThis move deepens InnoCare’s push beyond oncology into chronic inflammatory skin diseases, targeting a large, under-served CSU patient population in China that requires long-term treatment.\nWe’ll now examine how advancing soficitinib into Phase II/III for chronic...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/is-innocare-pharma-sehk9969-quietly-recasting-its-future-aro","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/is-innocare-pharma-sehk9969-quietly-recasting-its-future-aro","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","09969","BK1161"],"gpt_icon":0},{"id":"1148261323","title":"HK Stock Movement | INNOCARE (09969) Rises Over 4% as Self-Developed Novel TYK2 Inhibitor ICP-332 Gains Approval for Phase II/III Clinical Trials in CSU Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1148261323","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148261323?lang=en_us&edition=fundamental","pubTime":"2025-12-19 11:24","pubTimestamp":1766114688,"startTime":"0","endTime":"0","summary":"INNOCARE (09969) surged more than 4%, reaching HK$13.69 by the time of writing, with a trading volume of HK$37.91 million. On December 18, the company announced via its official WeChat account that...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["III","BK4134","09969","BK1161","BK1574","BK0239","688428"],"gpt_icon":0},{"id":"2591692630","title":"InnoCare Pharma Receives Regulatory Approval to Begin Clinical Trial of Drug in Systemic Lupus","url":"https://stock-news.laohu8.com/highlight/detail?id=2591692630","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591692630?lang=en_us&edition=fundamental","pubTime":"2025-12-15 12:36","pubTimestamp":1765773407,"startTime":"0","endTime":"0","summary":"InnoCare Pharma  said it secured regulatory approval to begin a phase 3 clinical trial of orelabrutinib in systemic lupus erythematosus, according to a Hong Kong bourse filing Sunday.Shares of the pharmaceutical company fell nearly 2% in late morning trade Monday.The company plans to recruit the first patient in the study during the first quarter of 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["09969","BK1161","BK1574"],"gpt_icon":0},{"id":"2591898695","title":"InnoCare Pharma (SEHK:9969): Assessing Valuation After Landmark NTRK Solid-Tumor Approval for Zurletrectinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2591898695","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591898695?lang=en_us&edition=fundamental","pubTime":"2025-12-15 01:30","pubTimestamp":1765733420,"startTime":"0","endTime":"0","summary":"InnoCare Pharma (SEHK:9969) just cleared a major milestone, with China’s regulator approving its next generation TRK inhibitor zurletrectinib for NTRK fusion positive solid tumors, the company’s first green light in solid cancers.\nSee our latest analysis for InnoCare Pharma.\nThe zurletrectinib approval lands after a volatile stretch, with InnoCare’s share price still up strongly this year thanks to a 150.79% year to date share price return. At the same time, the 90 day share price return of...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/innocare-pharma-sehk9969-assessing-valuation-after-landmark","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/innocare-pharma-sehk9969-assessing-valuation-after-landmark","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LARK","09969","BK4211","BK1161","BK1574"],"gpt_icon":0}],"profile":{"websiteUrl":"https://cn.innocarepharma.com","stockEarnings":[{"period":"1week","weight":0.0894},{"period":"1month","weight":-0.0514},{"period":"3month","weight":-0.1018},{"period":"6month","weight":-0.2759},{"period":"1year","weight":0.3097},{"period":"ytd","weight":-0.0098}],"compareEarnings":[{"period":"1week","weight":0.0074},{"period":"1month","weight":-0.0226},{"period":"3month","weight":0.0164},{"period":"6month","weight":-0.0048},{"period":"1year","weight":0.0915},{"period":"ytd","weight":0.0129}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"InnoCare Pharma Ltd is a China-based company mainly engaged in the research and development, production and commercialization of biopharmaceuticals. The Company focuses on areas with unmet clinical needs, such as oncology and autoimmune diseases. The Company's primary product pipeline includes Orelabrutinib, Tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-B05, ICP-332, ICP-488, ICP-192, ICP-723, ICP-033 and ICP-189, and others. Its products are mainly used to treat hematological tumors, solid tumors and autoimmune diseases. The Company is also developing products for the treatment of autoimmune diseases caused by abnormal T cell function. The Company conducts its businesses in domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.103999},{"month":2,"riseRate":0.666667,"avgChangeRate":0.128923},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.029218},{"month":4,"riseRate":0.666667,"avgChangeRate":0.116223},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.042592},{"month":6,"riseRate":0.833333,"avgChangeRate":0.12939},{"month":7,"riseRate":0.5,"avgChangeRate":0.039258},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.082108},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.024907},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.033299},{"month":11,"riseRate":0.833333,"avgChangeRate":0.100833},{"month":12,"riseRate":0.5,"avgChangeRate":-0.012645}],"exchange":"SEHK","name":"INNOCARE","nameEN":"INNOCARE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"INNOCARE(09969),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest INNOCARE(09969) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"INNOCARE,09969,INNOCARE股票,INNOCARE股票老虎,INNOCARE股票老虎国际,INNOCARE行情,INNOCARE股票行情,INNOCARE股价,INNOCARE股市,INNOCARE股票价格,INNOCARE股票交易,INNOCARE股票购买,INNOCARE股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"INNOCARE(09969),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest INNOCARE(09969) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}